Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $18.22 USD
Change Today 0.00 / 0.00%
Volume 0.0
RCDTF On Other Exchanges
Symbol
Exchange
RCDTF is not on other exchanges.
As of 8:10 PM 03/18/15 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (RCDTF) Snapshot

Open
$18.28
Previous Close
$18.22
Day High
$18.28
Day Low
$18.22
52 Week High
03/18/15 - $18.28
52 Week Low
05/29/14 - $16.70
Market Cap
4.0B
Average Volume 10 Days
176.0
EPS TTM
--
Shares Outstanding
209.1M
EX-Date
04/20/15
P/E TM
--
Dividend
$0.54
Dividend Yield
2.61%
Current Stock Chart for RECORDATI SPA (RCDTF)

Related News

No related news articles were found.

recordati spa (RCDTF) Related Businessweek News

No Related Businessweek News Found

recordati spa (RCDTF) Details

Recordati S.p.A. engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, and generics. It primarily offers Zanidip (lercanidipine), a calcium channel blocker for the treatment of hypertension. The company’s product development pipeline includes Carbaglu, which is approved in the European Union and is under Phase III clinical trial in the United States for the treatment of organic acidemias; Zanipress that is approved in the European Union to treat essential hypertension; and Cystadrops that is under pre-registration in the European Union for the treatment of ocular cystinosis. Its product development pipeline also includes methadone that is under phase III b clinical trial to treat cancer related pain; Citrafleet, which is under Phase III clinical trials for colonoscopy; Graspa, which is under pre-filing stage in the European Union for acute lymphoblastic leukemia, as well as under phase II b clinical trials for acute myeloid leukemia; and REC 0438 that is under phase I clinical trial in the European Union for treating overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active pharmaceutical ingredients and intermediates. It has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy.

3,923 Employees
Last Reported Date: 03/6/15
Founded in 1926

recordati spa (RCDTF) Top Compensated Officers

Chairman, Chief Executive Officer and General...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2013.

recordati spa (RCDTF) Key Developments

Recordati to Propose Dividend

The Board of Directors of Recordati SpA will propose to the shareholders a dividend of 0.24 per share, in full balance of the interim 2014 dividend of 0.26, to be paid to all shares outstanding at ex-dividend date, excluding those in treasury stock, as from 22 April 2015 (record date 21 April 2015), with ex-dividend on 20 April 2015 (against presentation of coupon no. 15). The full 2014 dividend is therefore of 0.50 per share (0.33 per share in 2013).

Recordati SpA Reports Preliminary Consolidated Earnings Results for the Year Ended December 31, 2014

Recordati SpA reported preliminary consolidated earnings results for the year ended December 31, 2014. For the period, consolidated revenue was EUR 987.3 million, up by 4.9% compared to the preceding year. International sales grow by 7.8%. EBITDA, at 27.7% of sales, is EUR 273.8 million, an increase of 19.0% over the preceding year. Operating income, at 23.4% of sales, is EUR 231.0 million, an increase of 18.2%. Net income, at 16.3% of sales, is EUR 161.2 million, an increase of 20.6% over 2013. Net financial position at December 31, 2014 records a net debt of EUR 186.0 million.

Recordati SpA, 2014 Earnings Call, Feb 12, 2015

Recordati SpA, 2014 Earnings Call, Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCDTF:US $18.22 USD 0.00

RCDTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €17.29 EUR +0.37
Faes Farma SA €2.38 EUR +0.055
Ipsen SA €44.24 EUR +0.295
Meda AB kr136.80 SEK +1.10
Orion Oyj €26.64 EUR +0.38
View Industry Companies
 

Industry Analysis

RCDTF

Industry Average

Valuation RCDTF Industry Range
Price/Earnings 19.5x
Price/Sales 3.1x
Price/Book 3.9x
Price/Cash Flow 19.5x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit www.recordati.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.